Study to Investigate the Efficacy, Safety, and Tolerability of Topical HT-001 for the Treatment of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors

This study tests a topical (applied to the skin) treatment called HT-001 for the painful and disfiguring rash that is a common side effect of cancer drugs called EGFR inhibitors (EGFRIs). EGFRIs are used to treat cancers like lung, colorectal, and head-and-neck cancer, but the rash they cause can be so bothersome that patients sometimes need to reduce or stop their cancer treatment. You may be eligible if... - You are 18 or older and are taking an approved EGFR inhibitor for cancer - You have developed a rash or skin reaction (pustules, papules, or burning) as a side effect of the EGFRI - Your rash is grade 3 or below and affects no more than 30% of your body surface - Your ECOG performance status is 0–2 - Your expected life expectancy is at least 3 months You may NOT be eligible if... - Your rash is severe (grade 4) or affects more than 30% of your body - You have a history of eczema, psoriasis, or other chronic skin conditions - You are receiving radiation to the head, neck, or upper chest at the same time as EGFRI therapy - You are pregnant or breastfeeding - You have a known allergy to aprepitant or any component of HT-001 Talk to your doctor to see if this trial is right for you.